Kiniksa Pharmaceuticals (KNSA) holder to sell 3,673 Class A shares under Rule 144

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals, Ltd. has a holder planning to sell 3,673 Class A ordinary shares under Rule 144 through Charles Schwab & Co., Inc. The shares have an aggregate market value of $299,092.00. Class A ordinary shares outstanding were 48,289,273 and are listed on NASDAQ.

Recent equity compensation-related activity includes restricted stock lapses of 500 shares on June 29, 2023 and 3,173 shares on June 5, 2025.

Key Figures

Shares to be sold: 3,673 shares Aggregate market value: $299,092.00 Shares outstanding: 48,289,273 shares +2 more

5 metrics

Shares to be sold 3,673 shares Class A ordinary shares planned for sale under Rule 144

Aggregate market value $299,092.00 Value of 3,673 Class A ordinary shares to be sold

Shares outstanding 48,289,273 shares Class A ordinary shares outstanding for Kiniksa Pharmaceuticals, Ltd.

Restricted stock lapse 500 shares Equity compensation-related restricted stock lapse on 06/29/2023

Restricted stock lapse 3,173 shares Equity compensation-related restricted stock lapse on 06/05/2025

Key Terms

Form 144, Restricted Stock Lapse, Equity Compensation

3 terms

Form 144 regulatory

"144: Filer Information 144: Issuer Information 144: Securities Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Lapse financial

"Class A Ordinary Share | 06/29/2023 | Restricted Stock Lapse"

Equity Compensation financial

"06/29/2023 | Equity Compensation Class A Ordinary Share"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:02 PM Accepted by SEC EDGAR 07/29/2026 - 04:02 PM Learn about SEC filing dates

FAQ

What does Kiniksa Pharmaceuticals (KNSA) disclose in this Form 144?

Kiniksa Pharmaceuticals discloses that a holder intends to sell 3,673 Class A ordinary shares under Rule 144 through Charles Schwab & Co., Inc., with an aggregate market value of $299,092.00 on the NASDAQ market.

How many Kiniksa (KNSA) shares are planned for sale under Rule 144?

The filing reports a planned sale of 3,673 Class A ordinary shares of Kiniksa Pharmaceuticals, Ltd. These shares are to be sold through Charles Schwab & Co., Inc. as broker on the NASDAQ market.

What is the aggregate market value of KNSA shares in this planned Rule 144 sale?

The aggregate market value of the planned Rule 144 sale is $299,092.00 for 3,673 Class A ordinary shares of Kiniksa Pharmaceuticals, Ltd., as reported in the Form 144 filing.

How many Kiniksa Pharmaceuticals (KNSA) Class A shares are outstanding?

The Form 144 states that 48,289,273 Class A ordinary shares of Kiniksa Pharmaceuticals, Ltd. are outstanding. This figure provides context for the planned sale of 3,673 shares under Rule 144.

What recent equity compensation events does KNSA report in connection with this Form 144?

The filing lists restricted stock lapses tied to equity compensation: 500 shares on June 29, 2023 and 3,173 shares on June 5, 2025, both involving Kiniksa Pharmaceuticals, Ltd. Class A ordinary shares.

On which market are Kiniksa Pharmaceuticals (KNSA) shares traded in this Form 144?

The Form 144 indicates that Kiniksa Pharmaceuticals, Ltd. Class A ordinary shares are traded on NASDAQ. The planned Rule 144 sale of 3,673 shares is expected to occur on this market through Charles Schwab & Co., Inc.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	3673	299092.00	48289273	07/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	06/29/2023	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			500	06/29/2023	Equity Compensation
Class A Ordinary Share	06/05/2025	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			3173	06/05/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)